STOCK TITAN

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Positive)
Tags

Dr. Reddy's Laboratories has achieved a significant milestone by ranking 15th in Science magazine's 2024 Top Biotech and Pharma Employers Survey, marking its third consecutive appearance on the prestigious list. The company improved from its previous rankings of 18th in 2022 and 16th in 2023, scoring particularly well in 'Employee Respect', 'Employee Loyalty', and 'Social Responsibility'.

The survey, conducted from March to April 2024, gathered approximately 6,400 responses globally, with participants evaluating companies across 24 characteristics. Notably, Dr. Reddy's was also ranked first among Indian pharma companies in both R&D intensity and proportion of PhD employees according to a recent FAST India report.

Dr. Reddy's Laboratories ha raggiunto un traguardo significativo classificandosi 15° nell'indagine dei Top Biotech e Pharma Employers 2024 della rivista Science, segnando la sua terza apparizione consecutiva in questa prestigiosa lista. L'azienda è migliorata rispetto alle sue precedenti classifiche, 18° nel 2022 e 16° nel 2023, ottenendo punteggi particolarmente buoni in 'Rispetto per i Dipendenti', '' e 'Responsabilità Sociale'.

L'indagine, condotta da marzo ad aprile 2024, ha raccolto circa 6.400 risposte a livello globale, con i partecipanti che hanno valutato le aziende su 24 caratteristiche. È interessante notare che Dr. Reddy's è stata anche classificata al primo posto tra le aziende farmaceutiche indiane sia in intensità di R&S che nella proporzione di dipendenti con dottorato secondo un recente rapporto di FAST India.

Dr. Reddy's Laboratories ha logrado un hito significativo al clasificarse en el 15° lugar en la encuesta de los Mejores Empleadores Biotecnológicos y Farmacéuticos 2024 de la revista Science, marcando su tercera aparición consecutiva en esta prestigiosa lista. La empresa mejoró respecto a sus clasificaciones anteriores, que fueron 18° en 2022 y 16° en 2023, obteniendo puntuaciones particularmente altas en 'Respeto por los Empleados', 'Lealtad de los Empleados' y 'Responsabilidad Social'.

La encuesta, realizada de marzo a abril de 2024, recopiló aproximadamente 6,400 respuestas a nivel mundial, con los participantes evaluando empresas en 24 características. Notablemente, Dr. Reddy's también ocupó el primer lugar entre las compañías farmacéuticas indias en términos de intensidad de I+D y proporción de empleados con doctorado, según un reciente informe de FAST India.

드. 레디의 연구소는 과학 잡지의 2024년 최고의 생명공학 및 제약 고용주 조사에서 15위에 오르는 중요한 이정표를 세웠으며, 이는 그들의 연속적인 세 번째 등장입니다. 이 회사는 2022년에 18위, 2023년에 16위로 발전하며 '직원 존중', '직원 충성도', '사회적 책임' 항목에서 특히 좋은 점수를 받았습니다.

이 조사는 2024년 3월부터 4월까지 전 세계적으로 약 6,400개의 응답을 수집했으며, 참가자들은 24가지 특성에 따라 회사를 평가했습니다. 특히 드. 레디는 최근 FAST 인도 보고서에 따르면 인도 제약 회사들 중 R&D 강도와 박사 직원 비율에서 1위를 차지했습니다.

Dr. Reddy's Laboratories a atteint un jalon important en se classant 15ème dans le classement 2024 des meilleurs employeurs biopharmaceutiques selon le magazine Science, marquant sa troisième apparition consécutive dans cette liste prestigieuse. L'entreprise a progressé par rapport à ses classements précédents, se plaçant 18ème en 2022 et 16ème en 2023, obtenant des scores particulièrement élevés dans les catégories 'Respect des employés', 'Fidélité des employés' et 'Responsabilité sociale'.

La sondage, mené de mars à avril 2024, a recueilli environ 6 400 réponses dans le monde entier, les participants évaluant les entreprises sur 24 caractéristiques. Notamment, Dr. Reddy's a également été classée au premier rang parmi les entreprises pharmaceutiques indiennes en termes de nombre de recherches et de développement et de proportion d'employés titulaires d'un doctorat, selon un rapport récent de FAST India.

Dr. Reddy's Laboratories hat einen bedeutenden Meilenstein erreicht, indem es im Arbeitgeber-Ranking 2024 der Biotech- und Pharma-Branche in der Zeitschrift Science den 15. Platz belegt hat. Dies ist das dritte aufeinanderfolgende Mal, dass das Unternehmen in dieser renommierten Liste erscheint. Das Unternehmen hat sich von den vorherigen Platzierungen (18. in 2022 und 16. in 2023) verbessert und hat besonders gut in den Kategorien 'Respekt für Mitarbeiter', 'Mitarbeitertreue' und 'Soziale Verantwortung' abgeschnitten.

Die Umfrage, die von März bis April 2024 durchgeführt wurde, sammelte weltweit etwa 6.400 Antworten, wobei die Teilnehmer Unternehmen anhand von 24 Merkmalen bewerteten. Bemerkenswerterweise wurde Dr. Reddy's auch bei indischen Pharmaunternehmen als erstes in Bezug auf F&E-Intensität und den Anteil an Mitarbeitern mit Doktortitel eingestuft, laut einem aktuellen Bericht von FAST India.

Positive
  • None.
Negative
  • None.

HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Survey conducted by Science.

This marks the third consecutive appearance of Dr. Reddy’s in the list. In 2022, Dr. Reddy’s entered the prestigious list at rank 18. In 2023, the company was placed at number 16. In the latest 2024 rankings, Dr. Reddy’s is placed at number 15 with high scores in ‘Employee Respect’, ‘Employee Loyalty’ and ‘Social Responsibility’. The full list is available here: https://www.science.org/content/article/top-20-2024-who-did-science-readers-select-best-biopharma

The prestigious Science magazine is a U.S.-based peer-reviewed academic journal of the American Association for the Advancement of Science (AAAS) and one of the world's top academic journals. Since 2002, Science magazine has evaluated top organizations in biotech, pharma, and biopharma through its Top Employers Survey. The Science and Science Careers’ 2024 Top Employers Survey polled employees in biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers as well as their driving characteristics. Respondents to the web-based survey were asked to rate companies based on 24 characteristics, including innovative leadership, respect for employees, and social responsibility. The findings are based on approximately 6,400 completed surveys from readers of Science, and other survey invitees.

Commenting on the recognition, G.V. Prasad, Co-Chairman and Managing Director of Dr. Reddy’s said, “We stand for developing affordable and innovative pharmaceuticals by investing in cutting-edge science and technology, developing great scientists and creating an environment that nurtures innovation in all aspects of product development. Our colleagues have the freedom to pursue multiple career tracks within the organization and we expose them to the best ideas and knowledge in whatever field they choose to work in. Our culture and identity have revolved around being bold, entrepreneurial, responsible, humble, empathetic. Our purpose of ‘Good Health Can’t Wait’ is a movement and call to action for all of us, and good health encompasses patients, people and planet. The opportunity is available to each colleague to do their life’s work at our company and make the world a better place. Our people are our pride, and nothing gives us more joy than to see our people realize their full potential in the company.”

A recent report by the Foundation for Advancing Science and Technology (FAST India) in collaboration with IIFL Securities on ‘State of Industry R&D in India’ ranked Dr. Reddy’s first among Indian pharma companies in both R&D intensity and the proportion of PhD employees1.

Note on methodology:

Science Careers, a part of the American Association for the Advancement of Science (AAAS), commissioned Cell Associates and The Brighton Consulting Group to conduct a web-based survey aimed at determining the companies in the biotechnology and pharmaceutical industries with the best reputations as employers. This web-based study was conducted from March 1 through April 7, 2024.

For this year’s survey, a mixed methodology was used. The first part of this methodology included emailed invitations to Science and Science Careers website visitors registered with AAAS as well as several social media posts. The second part of the methodology included email blasts to Human Resource contacts from the Science Careers database, asking them to promote the survey within their organizations.

This report is based on a total sample of approximately 6,400 surveys. A vast majority of the survey participants came from North America (65%), Europe (19%), and Asia/Pacific Rim (11%).

Survey respondents were asked to select the companies they considered best, average, and worst employers. They then rated these companies on 24 different attributes. Attribute categories included Corporate Image, Financial Prowess, Leadership and Direction, Work Culture and Environment, and Academic and Intellectual Challenge.

A mathematical process was used to determine the attributes with the greatest impact on company/employer reputation. Unique ranking scores were then derived from the ratings given to each company on these attributes. The 20 companies with the best reputations as employers were then determined from the list of companies that were each mentioned at least 35 times. The ranking for each company was independent of company size or number of votes.

About AAAS: The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal Science, as well as Science Translational Medicine; Science Signaling; a digital, open-access journal, Science Advances; Science Immunology; and Science Robotics. AAAS was founded in 1848, and includes more than 250 affiliated societies and academies of science, serving 10 million individuals. The nonprofit AAAS is open to all and fulfills its mission to “advance science and serve society” through initiatives in science policy, international programs, science education, public engagement, and more. For additional information about AAAS, see www.aaas.org.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

__________________________________
1 https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-pharma-firms-trail-global-peers-in-rd-innovation-and-talent-metrics-fast-india-iifl-securities/articleshow/114395822.cms?from=mdr

MEDIA RELATIONS

USHA IYER

USHAIYER@DRREDDYS.COM

Source: Dr. Reddy’s Laboratories Ltd.

FAQ

What rank did Dr. Reddy's (RDY) achieve in Science magazine's 2024 Top Employers Survey?

Dr. Reddy's ranked 15th in Science magazine's 2024 Top Biotech and Pharma Employers Survey.

How has Dr. Reddy's (RDY) ranking changed in Science magazine's survey over the past three years?

Dr. Reddy's ranking has steadily improved from 18th in 2022 to 16th in 2023, and now 15th in 2024.

What key attributes earned Dr. Reddy's (RDY) its top ranking in 2024?

Dr. Reddy's received high scores in Employee Respect, Employee Loyalty, and Social Responsibility.

How many participants were involved in Science magazine's 2024 employer survey?

The survey included approximately 6,400 completed surveys from Science readers and other survey invitees.

Dr. Reddy's Laboratories Limited American Depositary Shares

NYSE:RDY

RDY Rankings

RDY Latest News

RDY Stock Data

2.53B
166.82M
15.13%
1.32%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Hyderabad